G Protein-Coupled Receptor 35 Holds Potential as a Beacon of Hope for Treating Chondrosarcoma
References
- Hogendoorn PCW, Bovée JVMG, Nielsen GP. Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma. In: Fletcher CD, Bridge JA, Hogendoorn PCW, Mertens F, eds. World Health Organization Classification of Tumours of Soft Tissue and Bone. 5th ed. Vol 5. Lyon, France: IARC Press; 2013:264–268.
- Fletcher CD, Bridge JA, Hogendoorn PCW, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone: WHO Classification of Tumours, vol 5. 4th ed. Geneva, Switzerland: World Health Organization; 2013.
- Chow WA. Chondrosarcoma: biology, genetics, and epigenetics. F1000Res. 2018;7: F1000. doi:10.12688/f1000research.15953.1.
- Tarpey PS, Behjati S, Cooke SL, Van Loo P, Wedge DC, Pillay N, et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet. 2013;45(8):923–926. doi:10.1038/ng.2668.
- Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(4):1021–1031. doi: 10.1158/1535-7163.MCT-13-0639.
- Duffaud F, Italiano A, Bompas E, Rios M, Penel N, Mir O, et al. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. Eur J Cancer. 2021; 150:108–118. doi: 10.1016/j.ejca.2021.03.039.
- Campbell VT, Nadesan P, Ali SA, Wang CY, Whetstone H, Poon R, et al. Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth. Mol Cancer Ther. 2014;13(7):1259–1269. doi: 10.1158/1535-7163.MCT-13-0731.
- RefSeq. Jul 2008. Available from:
https://www.ncbi.nlm.nih.gov/refseq/ - Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Dębniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–5. doi:10.1086/426403.
- DepMap, Broad. DepMap 22Q2 Public. figshare. Published 2022.
- Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1(2):235–248. doi:10.1038/s43018-019-0018-6.
- Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–607. doi:10.1038/nature11003.
- Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357–W364. doi:10.1093/nar/gkz382.
- Daina A, Zoete V. Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning. Commun Chem. 2024;7(1):105. doi:10.1038/s42004-024-01179-2.
- Napolitano F, Sirci F, Carrella D, di Bernardo D. Drug-set enrichment analysis: A novel tool to investigate drug mode of action. Bioinformatics. 2016;32(2):235–241. doi:10.1093/bioinformatics/btv536.
- Gfeller, D., Michielin, O., and Zoete, V. (2013). Shaping the interaction landscape of bioactive molecules. Bioinformatics 29(23), 3073–3079.
- Dermawan JKT, Nafa K, Mohanty A, Xu Y, Rijo I, Casanova J, et al. Distinct IDH1/2-associated methylation profile and enrichment of TP53 and TERT mutations distinguish dedifferentiated chondrosarcoma from conventional chondrosarcoma. Cancer Res Commun. 2023;33(4):431–443. doi: 10.1158/2767-9764.CRC-22-0397.
- Perez Almeria CV, Setiawan IM, Siderius M, Smit MJ. G protein-coupled receptors as promising targets in cancer. Curr Opin Endocrinol Metab. 2021;16(2):119–127. doi: 10.1016/j.coemr.2020.10.005.
- Insel PA, Sriram K, Salmerón C, Wiley SZ. Proton-sensing G protein-coupled receptors: detectors of tumor acidosis and candidate drug targets. Future Med Chem. 2020;12(6):523–532. doi:10.4155/fmc-2019-0357.
- Müller-Lissner S. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013;9(4):391–401. doi:10.1517/17425255.2013.77 3972.
- Criddle DN. Reactive oxygen species, Ca(2+) stores and acute pancreatitis; a step closer to therapy? Cell Calcium. 2016;60(3):180–189. doi: 10.1016/j.ceca.2016.04.007.
- Ivanova H, Vervliet T, Missiaen L, Parys JB, De Smedt H, Bultynck G. Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival. Biochim Biophys Acta. 2014;1843(10):2164–2183. doi: 10.1016/j.bbamcr.2014.03.007.
- Dong J, Aulestia FJ, Kahn SA, Zeniou M, Dubois LG, El-Habr EA, et al. Bisacodyl and its cytotoxic activity on human glioblastoma stem-like cells: Implication of inositol 1,4,5-triphosphate receptor dependent calcium signaling. Biochim Biophys Acta Mol Cell Res. 2017;1864(6):1018–27. doi: 10.1016/j.bbamcr.2017.01.010.
- Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, et al. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012;2(7):638–51. doi:10.1158/2159-8290.CD-12-0093.
- Feve M, Zeniou-Meyer M, Haiech J, Chneiweiss H, Kilhoffer CM, Mameri S. US patent application publication No. US 2014/0186872 A1. Published 2014.
- Grunewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12(11):e11131. doi:10.15252/emmm.201911131.
- Boehme KA, Schleicher SB, Traub F, Rolauffs B. Chondrosarcoma: A rare misfortune in aging human cartilage? The role of stem and progenitor cells in proliferation, malignant degeneration, and therapeutic resistance. Int J Mol Sci. 2018;19(1):311. doi:10.3390/ijms19010311.
- Menendez ST, Gallego B, Murillo D, Rodriguez A, Rodriguez R. Cancer stem cells as a source of drug resistance in bone sarcomas. J Clin Med. 2021;10(12):262. doi:10.3390/jcm10122621.
- Rey V, Tornín J, Alba-Linares JJ, Robledo C, Murillo D, Rodríguez A, et al. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma. EBio-Medicine. 2024; 102:105090. doi: 10.1016/j.ebiom.2024.105090.
- Tlemsani C, Larousserie F, De Percin S, Audard V, Hadjadj D, Chen J, et al. Biology and management of high-grade chondrosarcoma: an update on targets and treatment options. Int J Mol Sci. 2023;24(2):1361. doi:10.3390/ijms24021361.
DOI: https://doi.org/10.2478/bjmg-2025-0013 | Journal eISSN: 2199-5761
Language: English
Published on: Oct 8, 2025
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
Related subjects:
© 2025 A Tuncal, R Kalkan, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.